NCT03555877: Anti-hormonal Therapy With or Without Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

NCT03555877
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled/untreated central nervous system lesions
https://ClinicalTrials.gov/show/NCT03555877

Comments are closed.

Up ↑